Patents by Inventor Stephen Gately

Stephen Gately has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
    Patent number: 11780816
    Abstract: The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of a HDAC isoform in a cell or with one or more of the aminobenzimidazole derivatives.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 10, 2023
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT
    Publication number: 20230143583
    Abstract: The present disclosure relates to certain amides and heterocyclic compounds and uses of these amides and heterocyclic compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
    Type: Application
    Filed: December 28, 2022
    Publication date: May 11, 2023
    Inventors: Tong Wang, Stephen Gately
  • Amide compounds as kinase inhibitors, compositions and methods of treatment
    Patent number: 11555039
    Abstract: The present disclosure relates to certain amides and heterocyclic compounds and uses of these amides and heterocyclic compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: January 17, 2023
    Assignee: Translational Drug Development LLC
    Inventors: Tong Wang, Stephen Gately
  • (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
    Publication number: 20220402884
    Abstract: The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.
    Type: Application
    Filed: August 17, 2022
    Publication date: December 22, 2022
    Inventors: Tong Wang, Stephen Gately
  • (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof
    Patent number: 11420947
    Abstract: The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: August 23, 2022
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE
    Publication number: 20220184040
    Abstract: The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of (S)-N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof. In certain embodiments of this method the malignant rhabdoid tumor is small cell cancer of the ovary of the hypercalcemic type (SCCOHT).
    Type: Application
    Filed: March 25, 2020
    Publication date: June 16, 2022
    Inventor: Stephen Gately
  • AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS, AND METHODS OF INHIBITING HISTONE DEACETYLASE
    Publication number: 20220153705
    Abstract: The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of a HDAC isoform in a cell or with one or more of the aminobenzimidazole derivatives.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Inventors: Tong Wang, Stephen Gately
  • Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
    Patent number: 11236052
    Abstract: The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of a HDAC isoform in a cell or with one or more of the aminobenzimidazole derivatives.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
    Publication number: 20210347747
    Abstract: The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.
    Type: Application
    Filed: June 10, 2021
    Publication date: November 11, 2021
    Inventors: Tong Wang, Stephen Gately
  • BENZAMIDE AND ACTIVE COMPOUND COMPOSITIONS AND METHODS OF USE
    Publication number: 20210093717
    Abstract: The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, a DNA demethylating agent, and/or an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: December 2, 2020
    Publication date: April 1, 2021
    Inventors: Tong Wang, Stephen Gately, Paul Gonzales
  • AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS, AND METHODS OF INHIBITING HISTONE DEACETYLASE
    Publication number: 20210061770
    Abstract: The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of a HDAC isoform in a cell or with one or more of the aminobenzimidazole derivatives.
    Type: Application
    Filed: September 6, 2018
    Publication date: March 4, 2021
    Inventors: Tong Wang, Stephen Gately
  • AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT
    Publication number: 20210047335
    Abstract: The present disclosure relates to certain amides and heterocyclic compounds and uses of these amides and heterocyclic compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 18, 2021
    Inventors: Tong Wang, Stephen Gately
  • Benzamide and active compound compositions and methods of use
    Patent number: 10881733
    Abstract: The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, or a DNA demethylating agent and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: January 5, 2021
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately, Paul Gonzales
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 10807966
    Abstract: The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 20, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • Benzamide and active compound compositions and methods of use
    Patent number: 10780080
    Abstract: The present invention describes compositions, including pharmaceutical compositions, comprising an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use include methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: September 22, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately, Paul Gonzales
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20200255448
    Abstract: The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventors: Tong Wang, Stephen Gately
  • Amide compounds as kinase inhibitors, compositions and methods of treatment
    Patent number: 10738007
    Abstract: The present disclosure relates to certain amides and heterocyclic compounds. The present disclosure also relates to uses of these compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graft versus host disease (GVHD), inflammation, cardiovascular disorders, central nervous system disorders, and neoplastic disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: August 11, 2020
    Assignee: Translation Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 10633393
    Abstract: The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 28, 2020
    Assignee: Translational Drug Development
    Inventors: Tong Wang, Stephen Gately
  • 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof
    Patent number: 10590088
    Abstract: Disclosed are 4-(benzimidazol-2-ylamino)benzamide derivatives useful in slowing the expansion of cancer cells and methods of synthesizing derivatives of formula 5 or formula 7: wherein R and R? are defined herein.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 17, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • Pyrazole compounds and methods of use thereof
    Patent number: 10584119
    Abstract: The present invention comprises compounds of Formula I and their use in the inhibition of cell proliferation in therapeutic treatments. Pharmaceutical compositions comprising at least one compound of Formula I and at least one pharmaceutical excipient are disclosed, as well as methods of using compounds of Formula I and pharmaceutical compositions thereof for treatment of hyper-proliferative diseases and other disorders.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 10, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately